Mohit Bansal
Stock Analyst at Wells Fargo
(4.54)
# 197
Out of 4,778 analysts
160
Total ratings
67.02%
Success rate
12.96%
Average return
Main Sectors:
Stocks Rated by Mohit Bansal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Maintains: Overweight | $970 → $1,100 | $852.34 | +29.06% | 17 | Mar 5, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $120 → $140 | $107.88 | +29.77% | 11 | Mar 5, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $210 → $240 | $201.31 | +19.22% | 8 | Mar 5, 2025 | |
| BIIB Biogen | Maintains: Equal-Weight | $165 → $140 | $139.18 | +0.59% | 13 | Feb 13, 2025 | |
| JAZZ Jazz Pharmaceuticals | Upgrades: Overweight | $130 → $170 | $135.20 | +25.74% | 2 | Feb 13, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Equal-Weight | $60 → $62 | $59.20 | +4.73% | 8 | Feb 7, 2025 | |
| VRTX Vertex Pharmaceuticals | Downgrades: Equal-Weight | $460 | $508.99 | -9.62% | 10 | Jan 30, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Equal-Weight | $62 → $57 | $64.85 | -12.10% | 6 | Jan 13, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $1,050 → $900 | $634.07 | +41.94% | 16 | Jan 10, 2025 | |
| AMGN Amgen | Maintains: Equal-Weight | $335 → $280 | $306.76 | -8.72% | 9 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $20.26 | +48.08% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $170 | $97.16 | +74.98% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $70 | $26.92 | +160.03% | 1 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $125 → $110 | $87.85 | +25.21% | 10 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 → $27 | $21.03 | +28.39% | 4 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $115 → $90 | $71.56 | +25.77% | 5 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $12 | $1.51 | +697.34% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $28 → $30 | $25.55 | +17.42% | 10 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $140 → $170 | $116.14 | +46.38% | 7 | Apr 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $16.77 | +61.00% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $34.95 | +43.06% | 1 | Nov 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,875 | $8.55 | +21,829.82% | 1 | Mar 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $30 | $29.03 | +3.34% | 4 | Jan 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $1.20 | +2,900.00% | 1 | Nov 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $19 | $16.35 | +16.24% | 3 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $5 | $0.25 | +1,884.91% | 3 | Apr 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $30 → $60 | $1.62 | +3,603.70% | 4 | Dec 3, 2019 |
Eli Lilly and Company
Mar 5, 2025
Maintains: Overweight
Price Target: $970 → $1,100
Current: $852.34
Upside: +29.06%
Gilead Sciences
Mar 5, 2025
Maintains: Overweight
Price Target: $120 → $140
Current: $107.88
Upside: +29.77%
AbbVie
Mar 5, 2025
Maintains: Overweight
Price Target: $210 → $240
Current: $201.31
Upside: +19.22%
Biogen
Feb 13, 2025
Maintains: Equal-Weight
Price Target: $165 → $140
Current: $139.18
Upside: +0.59%
Jazz Pharmaceuticals
Feb 13, 2025
Upgrades: Overweight
Price Target: $130 → $170
Current: $135.20
Upside: +25.74%
Bristol-Myers Squibb Company
Feb 7, 2025
Maintains: Equal-Weight
Price Target: $60 → $62
Current: $59.20
Upside: +4.73%
Vertex Pharmaceuticals
Jan 30, 2025
Downgrades: Equal-Weight
Price Target: $460
Current: $508.99
Upside: -9.62%
Halozyme Therapeutics
Jan 13, 2025
Maintains: Equal-Weight
Price Target: $62 → $57
Current: $64.85
Upside: -12.10%
Regeneron Pharmaceuticals
Jan 10, 2025
Maintains: Overweight
Price Target: $1,050 → $900
Current: $634.07
Upside: +41.94%
Amgen
Jan 10, 2025
Maintains: Equal-Weight
Price Target: $335 → $280
Current: $306.76
Upside: -8.72%
Dec 11, 2024
Initiates: Overweight
Price Target: $30
Current: $20.26
Upside: +48.08%
Dec 11, 2024
Initiates: Overweight
Price Target: $170
Current: $97.16
Upside: +74.98%
Nov 21, 2024
Initiates: Overweight
Price Target: $70
Current: $26.92
Upside: +160.03%
Nov 1, 2024
Maintains: Equal-Weight
Price Target: $125 → $110
Current: $87.85
Upside: +25.21%
Oct 21, 2024
Upgrades: Overweight
Price Target: $9 → $27
Current: $21.03
Upside: +28.39%
Sep 17, 2024
Maintains: Overweight
Price Target: $115 → $90
Current: $71.56
Upside: +25.77%
Aug 9, 2024
Maintains: Overweight
Price Target: $14 → $12
Current: $1.51
Upside: +697.34%
Jul 31, 2024
Maintains: Equal-Weight
Price Target: $28 → $30
Current: $25.55
Upside: +17.42%
Apr 24, 2024
Upgrades: Overweight
Price Target: $140 → $170
Current: $116.14
Upside: +46.38%
Mar 7, 2023
Initiates: Overweight
Price Target: $27
Current: $16.77
Upside: +61.00%
Nov 28, 2022
Initiates: Overweight
Price Target: $50
Current: $34.95
Upside: +43.06%
Mar 26, 2021
Initiates: Buy
Price Target: $1,875
Current: $8.55
Upside: +21,829.82%
Jan 7, 2021
Maintains: Buy
Price Target: $25 → $30
Current: $29.03
Upside: +3.34%
Nov 3, 2020
Initiates: Buy
Price Target: $36
Current: $1.20
Upside: +2,900.00%
Apr 30, 2020
Maintains: Buy
Price Target: $16 → $19
Current: $16.35
Upside: +16.24%
Apr 27, 2020
Maintains: Buy
Price Target: $8 → $5
Current: $0.25
Upside: +1,884.91%
Dec 3, 2019
Upgrades: Neutral
Price Target: $30 → $60
Current: $1.62
Upside: +3,603.70%